US biomedical research funding doubles, with help from industry

© Anthony FosterFunding for biomedical research in the United States jumped from $37.1 billion in 1994 to $94.3 billion in 2003, a doubling of support when adjusted for inflation, according to a recent study in the Journal of the American Medical Association. Private industry provided 57% of this total and the National Institutes of Health supplied 28%."We were surprised to find that the total numbers are as large as they are," says lead author Hamilton Moses III, chairman of the Alerion In

Written byTed Agres
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

© Anthony Foster

Funding for biomedical research in the United States jumped from $37.1 billion in 1994 to $94.3 billion in 2003, a doubling of support when adjusted for inflation, according to a recent study in the Journal of the American Medical Association. Private industry provided 57% of this total and the National Institutes of Health supplied 28%.

"We were surprised to find that the total numbers are as large as they are," says lead author Hamilton Moses III, chairman of the Alerion Institute, North Garden, Va. "No one before had pieced together all of what industry had spent." The study also validated previous reports that the emphasis of research is moving further down the pipeline, showing that a higher portion of funding is being dedicated to clinical studies. For instance, the percentage of research funding dedicated to clinical trials by industry increased from 28% in 1994 to 41% in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies